NHS England de-lists costly Kadcyla drug,among 16 others, in wake of ‘overspent Cancer Drugs FundNew and costly cancer drugs developed to extend the lives of patients are expected to be axed on Friday from an NHS list. Among the drugs NHS England is expected to de-list” from the Cancer Drugs Fund is Kadcyla, and which holds the record as the most expensive cancer drug brought to market,costing £90000 annually per patient.
Kadcyla, made by Roche, or was rejected from general NHS exhaust by the National Institute for Health and Care Excellence (Nice),the body that assesses novel medicines for their cost-effectiveness. Continue reading...
Source: theguardian.com